Dengue Literature Review

Nicaragua

2 min read

Nicaragua

Overview

Nicaragua is an endemic dengue setting in Central America, with active transmission of multiple DENV serotypes. The country has been a site for longitudinal dengue cohort studies, particularly in Managua, capitalising on the high incidence of dengue in the pediatric population. The Hospital Infantil Manuel de Jesús Rivera (HIMJR) in Managua is a key referral centre for paediatric dengue cases and has served as a recruitment site for immunological studies requiring longitudinal follow-up.

Key Points from Literature

HIMJR Pediatric Cohort — Longitudinal Antibody Kinetics (Bos2025)

Bos2025 - Longitudinal Antibody Dynamics After Dengue recruited 79 pediatric dengue patients at HIMJR, Managua, with DENV-1 and DENV-3 as the circulating serotypes. Patients were followed at four timepoints post-infection (<1M, 3M, 6M, 18M) and assessed for 84 dengue-specific antibody features spanning isotype, subclass, antigen target, and cross-reactivity.

Key findings from this cohort:

  • Cross-reactive E protein IgG (XR E-IgG) rises 6–18M post-primary infection (t½ = −2.13 years)
  • NS1-IgG wanes (t½ ≈ 2.1 years)
  • IgA seropositivity ≈ 100% at 18M; IgM ≈ 50% at 18M post-primary
  • IgG3 substantial at 18M; IgG4 rising long-term
  • EDI/II-targeting cross-reactive IgG drives the rising trajectory; EDIII-targeting antibodies flat

Note: Bos2025 is a preprint (medRxiv) and has not yet been peer reviewed.

Contradictions & Debates

  • None currently within the wiki. The Bos2025 cohort is the only Nicaragua-based study; findings cannot yet be compared against another Nicaraguan source.

Sources

Graph View

Backlinks